Vanda Pharma (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2026-02-11. Here's what investors need to know before the announcement.
Analysts estimate that Vanda Pharma will report an earnings per share (EPS) of $-1.67.
The market awaits Vanda Pharma's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Earnings Track Record
During the last quarter, the company reported an EPS beat by $0.02, leading to a 20.15% drop in the share price on the subsequent day.
Here's a look at Vanda Pharma's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.40 | -0.34 | -0.02 | -0.14 |
| EPS Actual | -0.38 | -0.46 | -0.50 | -0.08 |
| Price Change % | -20.00 | -2.00 | -4.00 | -6.00 |
Stock Performance
Shares of Vanda Pharma were trading at $7.51 as of February 09. Over the last 52-week period, shares are up 58.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Insights Shared by Analysts on Vanda Pharma
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vanda Pharma.
The consensus rating for Vanda Pharma is Buy, based on 4 analyst ratings. With an average one-year price target of $15.88, there's a potential 111.45% upside.
Peer Ratings Comparison
The analysis below examines the analyst ratings and average 1-year price targets of Invivyd, Kamada and Organogenesis Holdings, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
- Analysts currently favor an Buy trajectory for Invivyd, with an average 1-year price target of $10.0, suggesting a potential 33.16% upside.
- Analysts currently favor an Buy trajectory for Kamada, with an average 1-year price target of $13.0, suggesting a potential 73.1% upside.
- Analysts currently favor an Buy trajectory for Organogenesis Holdings, with an average 1-year price target of $9.0, suggesting a potential 19.84% upside.
Snapshot: Peer Analysis
The peer analysis summary offers a detailed examination of key metrics for Invivyd, Kamada and Organogenesis Holdings, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Vanda Pharmaceuticals | Buy | 18.06% | $53.30M | -4.74% |
| Invivyd | Buy | 41.17% | $12.04M | -15.41% |
| Kamada | Buy | 12.63% | $19.76M | 2.02% |
| Organogenesis Holdings | Buy | 30.66% | $114.24M | 5.95% |
Key Takeaway:
Vanda Pharma ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
All You Need to Know About Vanda Pharma
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Financial Insights: Vanda Pharma
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Vanda Pharma's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 18.06%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Vanda Pharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -40.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.74%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.68%, the company showcases effective utilization of assets.
Debt Management: Vanda Pharma's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
To track all earnings releases for Vanda Pharma visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!